Celgene 2nd-qtr beats expectations, as B-MS takeover closing pushed back

31 July 2019
celgene_sign_large

US biotech Celgene (Nasdaq: CELG) has reported second-quarter 2019 earnings that beat Wall Street expectations. Profit in the latest quarter rose to $1.571 billion, or $2.16 a share, from $1.045 billion, or $1.43 a share, in the year-earlier quarter.

Adjusted earnings per share (EPS) were $2.86, topping the $2.63 a share predicted by FactSet analysts. Revenue rose 15% to $4.4 billion from $3.814 billion a year ago, topping the FactSet consensus of $4.235 billion, said Celgene, currently the subject of a $74 billion takeover by US pharma major Bristol-Myers Squibb (NYSE: BMY).

Celgene’s shares dipped 0.4% to $92.61 by close of trading on Tuesday but edged up 0.o43% to $92.65 pre-market today.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology